Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories
By LabMedica International staff writers Posted on 05 May 2021 |

Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)
Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.
The clinical laboratory has gone through trial by fire in 2020, where total testing was 245% of baseline volumes, with ~55% being SARS-CoV-2 molecular tests. Despite vaccines, many industry players suggest SARS-CoV-2 testing volumes would not be impacted in the near term, and the demand for COVID-19-related testing will continue through 2021 and potentially into 2022. This means that testing-volume pressure on labs is going to continue.
Labs of all sizes are facing the same challenges: shortage of laboratory technologists and technicians, historic financial pressures on hospitals and health systems, and physically and mentally exhausted laboratory professionals - a pre-pandemic problem that has since been exacerbated. However, the TLA solutions that cater to labs processing high-sample volumes are out of reach for smaller volume labs due to space requirements and infrastructure constraints.
With the DxA 5000 Fit, mid-sized labs can enjoy the same benefits as larger-volume lab. The DxA 5000 Fit’s comprehensive workflow automation reduces up to 80% of manual steps through pre-analytical, analytical and post-analytical automation, thereby conserving precious human resources to do higher-value clinical work. It offers intelligent routing with dynamically calculated route planning for rapid and consistent TAT, with STATs always prioritized to deliver results faster. Additionally, its flexible design can be adapted to meet a mid-volume lab's space and infrastructure constraints.
"At Beckman Coulter, we believe that medium-size labs should be able to leverage the benefits of automation to address their challenges. Just because your lab is not processing a higher number of samples, doesn't mean you have to sacrifice the benefits of intelligent laboratory automation and settle for a marginally automated workcell-plus solution," said Dr. Peter Soltani, senior vice president & general manager, hematology, urinalysis & workflow information technology solutions at Beckman Coulter. "This is why we have launched DxA 5000 Fit, the first compact workflow automation solution that's the right fit for mid-volume labs because automation should be for all labs."
The clinical laboratory has gone through trial by fire in 2020, where total testing was 245% of baseline volumes, with ~55% being SARS-CoV-2 molecular tests. Despite vaccines, many industry players suggest SARS-CoV-2 testing volumes would not be impacted in the near term, and the demand for COVID-19-related testing will continue through 2021 and potentially into 2022. This means that testing-volume pressure on labs is going to continue.
Labs of all sizes are facing the same challenges: shortage of laboratory technologists and technicians, historic financial pressures on hospitals and health systems, and physically and mentally exhausted laboratory professionals - a pre-pandemic problem that has since been exacerbated. However, the TLA solutions that cater to labs processing high-sample volumes are out of reach for smaller volume labs due to space requirements and infrastructure constraints.
With the DxA 5000 Fit, mid-sized labs can enjoy the same benefits as larger-volume lab. The DxA 5000 Fit’s comprehensive workflow automation reduces up to 80% of manual steps through pre-analytical, analytical and post-analytical automation, thereby conserving precious human resources to do higher-value clinical work. It offers intelligent routing with dynamically calculated route planning for rapid and consistent TAT, with STATs always prioritized to deliver results faster. Additionally, its flexible design can be adapted to meet a mid-volume lab's space and infrastructure constraints.
"At Beckman Coulter, we believe that medium-size labs should be able to leverage the benefits of automation to address their challenges. Just because your lab is not processing a higher number of samples, doesn't mean you have to sacrifice the benefits of intelligent laboratory automation and settle for a marginally automated workcell-plus solution," said Dr. Peter Soltani, senior vice president & general manager, hematology, urinalysis & workflow information technology solutions at Beckman Coulter. "This is why we have launched DxA 5000 Fit, the first compact workflow automation solution that's the right fit for mid-volume labs because automation should be for all labs."
Latest Industry News
- Quanterix Completes Acquisition of Akoya Biosciences
- Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
- AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
- Illumina Acquires SomaLogic to Accelerate Proteomics Business
- Qiagen and Gencurix Partner on Development of QIAcuity Digital PCR IVD Assay
- QIAGEN and Incyte Enter into Precision Medicine Collaboration
- bioMérieux Acquires Day Zero Diagnostics Solutions and Technologies
- Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic
- Fujirebio Collaborates with Stanford Medicine to Advance Infectious Disease Research
- QuidelOrtho to Acquire MDx Company LEX Diagnostics
- QIAGEN Enters into New Strategic Partnerships for Expanding MRD Testing Portfolio in Oncology
- Danaher and AstraZeneca Partner on Next Generation AI-Powered Diagnostics
- EuroMedLab 2025 Showcases Latest Technologies and Innovations in Laboratory Medicine
- Qiagen Acquires NGS Analysis Software Company Genoox
- Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
- Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
Newly-Cleared Technology a Game Changer for Diagnosis of Lyme Disease
Lyme disease is one of the fastest-growing infectious diseases, with approximately 476,000 cases diagnosed annually in the United States. The symptoms of Lyme disease, such as fever, headache, fatigue,... Read more
Innovative Liquid Biopsy Test Uses RNA to Detect Early-Stage Cancer
Detecting and diagnosing cancer, particularly in its early stages, remains a significant challenge. Liquid biopsies offer a promising non-invasive alternative to traditional biopsies, which require removing... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment
Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Low-Cost Biosensing Technology Detects Disease Biomarkers in Minutes
Rapid at-home tests for diseases like COVID-19 have become increasingly popular for their convenience, but they come with a major drawback: they are less sensitive than the tests performed in medical settings.... Read more